Memantine and acetylcholinesterase inhibitor treatment in cases of cdr 0.5 or questionable impairment

Journal of Alzheimer's Disease

Volumn 16, Issue 3, 2009, Pages 577-583

  McClendon, McKee J ^a   Hernandez, Santiago ^b   Smyth, Kathleen A ^a,b,c   Lerner, Alan J ^a,b,d,e  

^a University Memory   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e University Memory and Aging Center   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; CDR 0.5; Disparity; Ethnicity; Memantine; Mild cognitive impairment; Off label; Race

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

AGED; ALZHEIMER DISEASE; APATHY; ARTICLE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; CAUCASIAN; ETHNOLOGY; FACTUAL DATABASE; HISPANIC; HOSPITALIZATION; NEGRO; REGISTER; STATISTICAL MODEL; STATISTICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COMORBIDITY; DATABASES, FACTUAL; DOPAMINE AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; MALE; MEMANTINE; REGISTRIES; SEVERITY OF ILLNESS INDEX;

EID: 65549114155     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0994     Document Type: Article

References (36)

1. Lerner AJ, McClendon MJ, Sami SA, Ogrocki PK, Adams KB, Smyth KA (2008) Factors affecting usage patterns of memantine in Alzheimer disease. Alzheimer Dis Assoc Disord 22, 137-143.
2. Mehta K, Yin M, Resendez C, Yaffe K (2005) Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology 65, 159-162.
3. Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, Alpérovitch A (2008) Memantine Therapy for Alzheimer disease in real-world practice: An observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord 22, 125-130.
4. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414.
5. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992.
6. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58, 397-405.
7. Petersen RC, Morris JC (2005) Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62, 1160-1163.
8. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA (2006) The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20, 210-216.
9. McKhann G Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: reportofthe NINCDS-ADRDA work group underthe auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
10. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308.
11. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
12. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12, 233-239.
13. Yesavage J, Brink TL, Rose T, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17, 37-49.
14. Rasbash J, Steele F, Browne W, Prosser R. A User's Guide to MLwiN: Version 2.0. University of London: Centre for Multilevel Modeling, London, 2004.
15. Petersen RC, Thomas RG, Grundman M,Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-2388.
16. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS (2008) Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70, 2024-2035.
17. Reisberg B, Doody R, Stoffler A, Schmitt S, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341.
18. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gerge I (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317-324.
19. Pomara N, Ott BR, Peskind E, Resnick EM (2007) Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord 21, 60-64.
20. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Meman-tine MEM-MD-12 Study Group (2008) Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5, 83-89.
21. Ott BR, Blake LM, Kagan E, Resnick M, for the Meman-tine MEM-MD-11AB study group (2007) Open label, multi-center, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J Neurol 254, 351-358.
22. Zdanys K, Tampi R (2008) A systematic review of off-label uses of memantine in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 32, 1362-1374.
23. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47, 351-354.
24. Barbu C, Ciuna A, Nose M, Levi D, Andretta M, Patten SF, Amaddeo F, Tansella M (2004) Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatr Scand 109, 275-278.
25. Datamonitor, Stakeholder Insight: Alzheimer's disease - Prescribing Trends Indicate That Neurologists Are Not Adhering to Guidelines, http://www.datamonitor.com/industries/ research/?pid=DMHC2255&type=Report. Accessed on November 20, 2008.
26. Jonville-Bera AP, Bera F, Autret-Leca E (2005) Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study. Eur J Clin Pharmacol 61, 231-236.
27. Win HK , Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA , Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS (2007) Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297, 2001-2009.
28. Lurie P, Tran T, Wolfe SM, Goodman R (2005) Violations of exhibiting and FDA rules at an American Psychiatric Association Annual Meeting. J Public Health Policy 26, 389-399.
29. McGinnis KA, Schulz R, Stone RA, Klinger J, Mercurio R (2006) Concordance of race or ethnicity of interventionists and caregivers of dementia patients: relationship to attrition and treatment outcomes in the REACH study. Gerontologist 46, 449-455.
30. Connell CM, Scott Roberts J, Mclaughlin SJ (2007) Public opinion about Alzheimer disease among blacks, Hispanics, and whites: results from a national survey. Alzheimer Dis Assoc Disord 21, 232-240.
31. Hipps YG, Roberts JS, Farrer LA, Green RC (2003). Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test 7, 39-44
32. Belle SH, Burgio L, Burns R, Coon D, Czaja SJ, Gallagher-Thompson D, Gitlin LN, Klinger J, Kopeke KM, Lee CC, Martindale-Adams J, Nichols L, Schulz R, Stahl S, Stevens A, Winter L, Zhang S (2006) Resources for Enhancing Alzheimer's Caregiver Health (REACH) II Investigators. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med 145, 727-738.
33. Han E, Liu G (2005) Racial disparities in prescription drug use for mental illness among populations in US. J Ment Health Policy Econ 8, 131-143.
34. Cummings JL, McRae T,Zhang R, Donepezil-Sertraline study group (2006) Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 14, 605-612.
35. Lerner AJ, Strauss M, Sami SA (2007) Recognizing apathy in Alzheimer's disease. Geriatrics 62, 14-17
36. Petrovic M, Hurt C, Collins D, Burns A, Camus V, Liperoti R, Marriott A, Nobili F, Robert P, Tsolaki M, Vellas B, Verhey F, Byrne EJ (2007) Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's disease consortium (EADC) study. Acta Clin Belg 62, 426-432.